Best Peptides for Weight Loss: GLP-1s, GH Peptides & More (2026 Guide)

Weight loss peptides are the fastest-growing category in the peptide space — and it's not even close. Driven by the GLP-1 revolution, peptides like semaglutide and tirzepatide have become household names, producing weight loss results that were previously unthinkable with pharmacotherapy alone. But GLP-1 agonists aren't the only game in town. Growth hormone peptides, mitochondrial peptides, and GH fragments all have varying degrees of evidence for fat loss and body composition improvement.

The problem? Most content online either hypes every peptide equally or buries the nuance. Not all weight loss peptides are created equal. Some have Phase 3 clinical trial data with thousands of participants and FDA approval. Others have a handful of small studies and promising mechanisms but limited human evidence. Knowing the difference matters — especially when you're deciding what to put in your body.

This guide ranks the most relevant peptides for weight loss into three tiers based on strength of evidence, then gives you a practical framework for choosing the right one for your goals.

Understanding Weight Loss Peptides: Three Categories

Before diving into individual compounds, it helps to understand the three major categories of peptides that affect body weight and fat loss. Each works through a fundamentally different mechanism, and understanding that mechanism tells you a lot about what to expect.

• •GLP-1 receptor agonists — These mimic or enhance the gut hormone GLP-1, which controls appetite, gastric emptying, and blood sugar regulation. They work primarily by making you eat less through central appetite suppression. This is where the strongest evidence lives.
• •Growth hormone peptides — These stimulate growth hormone release (secretagogues) or mimic GH fragments that target fat metabolism. They work indirectly — improving body composition by increasing lipolysis, preserving lean mass, and enhancing metabolic rate. The fat loss is real but more modest than GLP-1 agonists.
• •Metabolic peptides — These target cellular energy production, mitochondrial function, or enzyme pathways involved in fat storage. They're the newest and least-proven category, but some show genuine promise in early research.

The tiers below are organized by evidence quality and clinical significance — not by popularity or marketing claims.

Tier 1: GLP-1 Receptor Agonists (Strongest Evidence)

If you're looking for the most effective peptides for weight loss with the most clinical evidence behind them, this tier is where you start. These are FDA-approved medications with large-scale Phase 3 trials, real-world prescribing data, and well-characterized safety profiles.

Semaglutide

Semaglutide is a GLP-1 receptor agonist that mimics the satiety hormone your gut produces after meals. The natural hormone has a half-life of about 2 minutes; semaglutide's engineered structure extends that to approximately 7 days, enabling once-weekly subcutaneous injection. It's FDA-approved as Wegovy for chronic weight management and Ozempic for type 2 diabetes.

The STEP trial program provides the landmark evidence. In STEP 1 (n=1,961), participants on semaglutide 2.4 mg lost an average of 14.9% of body weight over 68 weeks, compared to 2.4% with placebo. About one-third of participants lost 20% or more. The 2-year STEP 5 data confirmed sustained efficacy at 15.2% weight loss at 104 weeks.

Beyond weight loss, the SELECT cardiovascular outcomes trial demonstrated a 20% reduction in major adverse cardiovascular events — making semaglutide the first obesity medication to show direct cardiovascular benefit.

Typical weight loss: 15–17% of body weight at maximum dose over 12–18 months. Dosing: Titrate from 0.25 mg/week up to 2.4 mg/week over 16+ weeks. Cost: ~$1,300/month brand-name; ~$50–150/month compounded.

For a deep dive, see our semaglutide research page and semaglutide weight loss guide.

Tirzepatide

Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first in its class. While semaglutide activates only GLP-1 receptors, tirzepatide simultaneously activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual mechanism provides additive appetite suppression, enhanced fat oxidation, and improved lipid metabolism beyond what GLP-1 alone achieves.

The SURMOUNT trials produced the highest weight loss numbers ever seen in obesity pharmacotherapy. In SURMOUNT-1 (n=2,539), participants on the 15 mg dose lost an average of 22.5% of body weight over 72 weeks. Over half lost 20% or more. SURMOUNT-3, which combined tirzepatide with intensive lifestyle intervention, showed an average of 26.6% weight loss — approaching what was previously only achievable with bariatric surgery.

Tirzepatide is FDA-approved as Zepbound for weight management and Mounjaro for type 2 diabetes.

Typical weight loss: 20–26% of body weight at maximum dose. Dosing: Titrate from 2.5 mg/week up to 15 mg/week over 16+ weeks. Cost: ~$1,000–1,200/month brand-name; ~$80–200/month compounded.

Learn more on our tirzepatide research page and our detailed semaglutide vs tirzepatide comparison.

Retatrutide

Retatrutide takes the multi-agonist approach one step further. It's a triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. The addition of glucagon receptor activation is significant — glucagon increases energy expenditure and hepatic fat oxidation, potentially addressing weight loss from both the appetite side (eating less) and the metabolic side (burning more).

Phase 2 trial data published in the New England Journal of Medicine showed that participants on the highest dose of retatrutide lost an average of 24.2% of body weight at 48 weeks. That's comparable to tirzepatide's best results but achieved in a shorter timeframe and at an earlier phase of clinical development. Some participants lost over 30% of their body weight.

Retatrutide is not yet FDA-approved — it's currently in Phase 3 trials. But the Phase 2 data is among the most impressive ever reported for any anti-obesity compound. If Phase 3 results hold up, retatrutide could become the most effective weight loss peptide available.

Typical weight loss: 24% at 48 weeks in Phase 2 (highest dose). Status: Phase 3 trials ongoing; not yet available by prescription. Availability: Research peptide only.

Read more on our retatrutide research page.

Tier 2: Growth Hormone Peptides (Moderate Evidence)

Growth hormone peptides don't suppress appetite like GLP-1 agonists. Instead, they promote fat loss indirectly by increasing growth hormone levels, which enhances lipolysis (fat breakdown), preserves lean muscle mass, and improves overall body composition. The weight loss is more modest — typically 3–8% of body weight — but the body composition changes can be meaningful, especially when combined with exercise and proper nutrition.

Tesamorelin

Tesamorelin is a growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary gland to produce and release growth hormone in a physiological pulsatile pattern. It's FDA-approved (brand name Egrifta) specifically for reducing excess visceral abdominal fat in HIV-positive patients with lipodystrophy — making it one of the few peptides with a fat-reduction-specific FDA indication.

Clinical trials in HIV-associated lipodystrophy showed tesamorelin reduced visceral adipose tissue (VAT) by approximately 15–18% over 26 weeks. It also improved trunk fat, waist circumference, and lipid profiles. Importantly, it achieved this without the supraphysiological GH levels associated with exogenous GH injection — the GH increase is more modest and physiologically regulated.

Outside the HIV population, tesamorelin is used off-label for general visceral fat reduction, anti-aging, and body composition improvement. The evidence in non-HIV populations is limited but the mechanism is well-understood.

Fat loss: 15–18% reduction in visceral fat (clinical trials). Dosing: 2 mg subcutaneous injection daily. Cost: ~$500–800/month brand-name; ~$100–200/month compounded.

See our tesamorelin research page for more details.

CJC-1295 + Ipamorelin Stack

The CJC-1295/Ipamorelin combination is the most popular growth hormone secretagogue stack for body composition improvement. CJC-1295 (with DAC) is a GHRH analog that extends GH-releasing hormone's half-life, while Ipamorelin is a selective ghrelin mimetic that triggers GH pulses without significantly raising cortisol or prolactin.

Together, they amplify natural GH production through complementary pathways — CJC-1295 raises the baseline and Ipamorelin triggers sharper peaks. The result is elevated GH and IGF-1 levels that promote fat oxidation, lean mass preservation, improved sleep quality, and better recovery.

The evidence for direct weight loss is indirect. There are no large-scale weight loss trials for this stack. However, multiple smaller studies show meaningful improvements in body composition — reduced body fat percentage with maintained or increased lean mass — particularly when combined with resistance training.

Expected results: Modest fat loss (3–6% body fat reduction over 3–6 months), improved muscle definition, better sleep and recovery. Dosing: Typically CJC-1295 2 mg 2x/week + Ipamorelin 200–300 mcg 1–2x daily. Cost: ~$100–250/month combined.

For stacking strategies, see our peptide stacking guide.

MK-677 (Ibutamoren)

MK-677 is an oral growth hormone secretagogue — technically a non-peptide ghrelin receptor agonist, but it's universally discussed alongside GH peptides because it achieves the same end result: sustained elevation of growth hormone and IGF-1 levels. Its oral bioavailability is a significant practical advantage over injectable GH peptides.

Clinical studies show MK-677 increases GH levels by approximately 40–60% and IGF-1 by 30–40% with daily oral dosing. It also improves sleep quality, nitrogen balance, and bone mineral density in various populations including elderly subjects.

The critical caveat for weight loss: MK-677 significantly increases appetite in most users because it activates ghrelin receptors — the same pathway that triggers hunger. This makes it potentially counterproductive for people whose primary goal is eating less to lose weight. Some users gain weight on MK-677 simply because they eat more. It's better suited for recomposition (losing fat while gaining muscle) in people who can manage their caloric intake despite increased hunger.

Expected results: Body composition improvement if calories are controlled; potential weight gain if appetite isn't managed. Dosing: 10–25 mg oral daily, typically at bedtime. Cost: ~$30–80/month.

Learn more on our MK-677 research page.

Tier 3: Research Peptides (Limited Evidence)

These peptides have interesting mechanisms and some preliminary data suggesting fat loss benefits, but they lack the large-scale clinical trials that would make them confident recommendations. They're included here because they're widely discussed in the peptide community and you should understand what the evidence actually shows — and what it doesn't.

AOD-9604

AOD-9604 is a modified fragment of human growth hormone (specifically amino acids 177–191) that was designed to isolate GH's fat-burning effects without its growth-promoting or diabetogenic effects. The theory is compelling: take the piece of GH that stimulates lipolysis and leave behind the parts that cause side effects.

In vitro and animal studies show AOD-9604 stimulates lipolysis and inhibits lipogenesis (fat creation) in fat cells. However, human clinical trial data is limited and mixed. A Phase 2b trial showed modest weight loss (~2.5 kg over 12 weeks at the highest dose) that did not reach statistical significance. The compound has not progressed through Phase 3 trials for weight loss, and it's not FDA-approved for any indication.

AOD-9604 was granted GRAS (Generally Recognized as Safe) status by the FDA as a food substance in 2014, which is sometimes cited as evidence of safety — but GRAS status for oral food use is very different from establishing safety and efficacy as an injectable therapeutic.

Expected results: Modest at best based on available data. Dosing: 250–300 mcg subcutaneous daily (research protocols). Cost: ~$40–80/month. Evidence level: Weak.

See our AOD-9604 research page for the full evidence breakdown.

MOTS-c

MOTS-c is a mitochondrial-derived peptide — a 16-amino-acid peptide encoded by the mitochondrial genome. It's sometimes called an "exercise mimetic" because it activates AMPK (the same pathway triggered by exercise and metformin) and improves cellular energy metabolism. MOTS-c enhances insulin sensitivity, increases glucose uptake in skeletal muscle, and promotes fatty acid oxidation.

Animal studies are promising. In mouse models, MOTS-c prevented diet-induced obesity, improved insulin resistance, and enhanced exercise capacity. A small human study showed that endogenous MOTS-c levels correlate with metabolic health and that levels decline with age and obesity — suggesting a potential therapeutic role for supplementation.

However, controlled human weight loss trials with exogenous MOTS-c do not yet exist. The peptide is at the very early stages of clinical development for metabolic applications. It's scientifically fascinating but not yet evidence-based for weight loss in humans.

Expected results: Unknown in humans for weight loss specifically. Dosing: 5–10 mg subcutaneous, 3–5x/week (research protocols). Cost: ~$80–150/month. Evidence level: Preclinical/early research.

Explore our MOTS-c research page for more on the science.

5-Amino-1MQ

5-Amino-1MQ is a small molecule (not technically a peptide) that inhibits the enzyme NNMT (nicotinamide N-methyltransferase). NNMT is overexpressed in fat tissue and plays a role in energy metabolism — inhibiting it appears to increase fat cell energy expenditure, activate the SAM (S-adenosylmethionine) metabolic cycle, and shrink fat cells.

In preclinical studies, NNMT inhibition reduced body weight and fat mass in diet-induced obese mice without affecting food intake — suggesting a mechanism distinct from appetite suppression. The compound is orally bioavailable, which is a practical advantage.

Human data is essentially nonexistent. There are no published clinical trials. 5-Amino-1MQ is widely available from research peptide suppliers and discussed in biohacking communities, but its efficacy and safety in humans are unproven. It's included here for completeness, not as a recommendation.

Expected results: Unknown in humans. Dosing: 50–100 mg oral daily (community protocols). Cost: ~$50–120/month. Evidence level: Preclinical only.

Comparison Table: All Weight Loss Peptides at a Glance

Here's how every peptide discussed in this guide compares across the most important factors:

*MK-677 increases appetite, which can be counterproductive for weight loss. Best suited for body recomposition with controlled caloric intake.

Which Peptide Should You Choose?

The right peptide depends on your specific goals, budget, risk tolerance, and how much evidence you require before trying something. Here's a practical decision framework:

If maximum weight loss is your primary goal:

Start with a GLP-1 agonist. Tirzepatide produces the highest weight loss in clinical trials (20–26%), followed by semaglutide (15–17%). If you have access to a prescribing physician and insurance coverage, these are the clear first choice. Retatrutide may eventually surpass both, but it's not yet FDA-approved. For a detailed head-to-head comparison, see our semaglutide vs tirzepatide guide.

If you want body recomposition (lose fat, preserve/gain muscle):

Consider growth hormone peptides like the CJC-1295/Ipamorelin stack or tesamorelin. These won't produce dramatic scale weight changes, but they can meaningfully shift your body composition — especially when paired with resistance training and adequate protein intake. They're also commonly stacked with GLP-1 agonists to offset GLP-1-associated muscle loss. See our stacking guide for combination protocols.

If you specifically need to target visceral fat:

Tesamorelin has the most specific evidence for visceral fat reduction — it's literally FDA-approved for that indication (in HIV patients). GLP-1 agonists also reduce visceral fat as part of overall weight loss, but tesamorelin targets it more directly through GH-mediated lipolysis.

If budget is a major constraint:

Compounded semaglutide ($50–150/month) or MK-677 ($30–80/month) are the most cost-effective options. Be aware that MK-677 increases appetite, so it requires disciplined caloric management. For semaglutide, source from a licensed 503B compounding facility and discuss with your healthcare provider.

If you're not comfortable with limited evidence:

Stick to Tier 1. Semaglutide and tirzepatide have the largest evidence base, established safety profiles, and FDA approval. AOD-9604, MOTS-c, and 5-Amino-1MQ have interesting science but insufficient human data to make confident recommendations. Tesamorelin is also FDA-approved, though for a different indication than general weight loss.

Side Effects to Consider

Different categories of weight loss peptides come with different side effect profiles. Understanding these upfront helps you choose wisely and prepare accordingly.

GLP-1 Agonists (Semaglutide, Tirzepatide, Retatrutide)

• Gastrointestinal effects are the primary challenge — nausea, diarrhea, constipation, and occasional vomiting. These affect 40–50% of users, are worst during dose titration, and usually improve over weeks. Eating smaller meals and avoiding fatty foods helps significantly.
• Muscle loss is a real concern. GLP-1s suppress appetite broadly, and without deliberate effort, 25–40% of weight lost can be lean mass. Prioritize high protein intake (0.7–1g per pound of lean mass) and resistance training.
• Gallbladder issues — rapid weight loss increases gallstone risk regardless of method. Report right-upper-quadrant pain immediately.
• Pancreatitis — rare but serious. Both semaglutide and tirzepatide carry this warning.
• Thyroid concerns — boxed warning for thyroid C-cell tumors based on rodent studies. Contraindicated in patients with MTC or MEN 2 history.

Growth Hormone Peptides (Tesamorelin, CJC-1295/Ipamorelin, MK-677)

• Water retention — the most common side effect of elevated GH. Expect some puffiness, especially in the first 2–4 weeks. It typically stabilizes.
• Joint pain and carpal tunnel symptoms — related to water retention and GH-mediated tissue growth. Usually dose-dependent and reversible.
• Increased appetite — particularly pronounced with MK-677. Can be counterproductive for weight loss goals.
• Blood sugar effects — GH is diabetogenic at high levels. Monitor fasting glucose, especially with prolonged use. MK-677 in particular has been shown to impair glucose tolerance in some studies.
• Numbness and tingling — paraesthesias from fluid shifts, usually mild and temporary.

Research Peptides (AOD-9604, MOTS-c, 5-Amino-1MQ)

The honest answer is that side effect profiles for these compounds are not well-characterized in humans. AOD-9604 appeared well-tolerated in its limited clinical trials. MOTS-c and 5-Amino-1MQ lack sufficient human safety data to make definitive statements. This uncertainty is itself a risk factor to weigh in your decision-making.

Track Your Weight Loss Protocol

Whichever weight loss peptide you choose, consistent tracking is what separates people who get results from people who guess. Recording your dose, injection schedule, weight trends, body measurements, side effects, and dietary intake gives you objective data to make informed adjustments — and gives your healthcare provider the information they need to optimize your protocol.

This is especially important during GLP-1 titration, where dose timing and side effect management directly impact outcomes. Track when you inject, how you feel in the 48 hours afterward, what and how much you eat, and how your weight trends week over week — not day to day.

Peptide Assistant is built for exactly this. Log your doses, track weight and body composition over time, note side effects by severity, and monitor your titration progress — all in one place. It's free, works on any device, and keeps your data private.

Explore individual peptide profiles in our research library, or dive deeper with our semaglutide guide, semaglutide vs tirzepatide comparison, and peptide stacking guide.